ASX Announcements

Five-Year Post-LEAD Review Shows Improvement in 2RT® Treatment Benefits for iAMD

ASX Announcement General AlphaRET

5 Mar, 2021

Clinical Trial to Assess Efficacy and Safety of iTrack™ in the Treatment of Mild to Moderate Glaucoma

ASX Announcement General iTrack

2 Mar, 2021

First Half FY2021 Accounts

ASX Announcement General

25 Feb, 2021

1HFY21: Growth in Glaucoma Surgical Devices Segment Despite Pandemic

ASX Announcement General

25 Feb, 2021

Notice of Upcoming Investor Call – First Half FY21 Results

ASX Announcement General

18 Feb, 2021

Notice of Change of Interests of Substantial holder

ASX Announcement General

14 Dec, 2020

Appendix 3G Issue of Options and Performance Rights

ASX Announcement General

9 Dec, 2020

Appendix 2A

ASX Announcement General

9 Dec, 2020

Poll Results Annual General Meeting 2020

ASX Announcement General

27 Nov, 2020

Chairman’s Address to Annual General Meeting

ASX Announcement General

27 Nov, 2020

PRESENTATION AND UPDATE, ANNUAL GENERAL MEETING 2020

ASX Announcement General

27 Nov, 2020

Strong Rebound for Glaucoma Surgical Device Sales in FY21

ASX Announcement General

25 Nov, 2020

2RT® Clinical Update: Sub-Study Analysis of LEAD Trial Demonstrates Improved Retinal Function Following Treatment with 2RT®

ASX Announcement General

16 Nov, 2020

Notice of Annual General Meeting

ASX Announcement General

26 Oct, 2020

Nova Eye Medical Establishes AlphaRET to Support Commercial Development of 2RT®

ASX Announcement AlphaRET

26 Oct, 2020

Date of AGM and Closing Date for Director Nominations

ASX Announcement General

8 Oct, 2020

Change in Substantial Holding (Australian Ethical)

ASX Announcement General

18 Sep, 2020

Change in Substantial Holding (Australian Ethical)

ASX Announcement General

10 Sep, 2020

New Director Appointment

ASX Announcement General

31 Aug, 2020

Notice of Upcoming Investor Call

ASX Announcement General

28 Aug, 2020

Nova Eye Records FY20 Net Profit After Tax of $35.7 Million

ASX Announcement General

28 Aug, 2020

Multicentre Study Highlights Surgical Efficiency of the Molteno3® Glaucoma Drainage Device

ASX Announcement Molteno3

5 Aug, 2020

Nova Eye Medical Completes Acquisition of Molteno Ophthalmology Assets

ASX Announcement General Molteno3

3 Aug, 2020

Payment to Shareholders of Capital Return and Dividend

ASX Announcement General

29 Jul, 2020

Updated Timetable for Capital Return & Dividend Payment

ASX Announcement General

16 Jul, 2020

Nova Eye Medical Expands Glaucoma Treatment Portfolio Through Acquisition of the Molteno3®

ASX Announcement General Molteno3

2 Jul, 2020

Appendix 3Z (Mangano)

ASX Announcement General

30 Jun, 2020

Appendix 3X (Spurling)

ASX Announcement General

30 Jun, 2020

Appendix 4E & Annual Report

ASX Announcement General

30 Jun, 2020

ASX ELX Completion Announcement

ASX Announcement General

30 Jun, 2020

For investor enquires please contact:

Dr. Tom Duthy
Nova Eye Medical Limited
W +61 402 493 727
tduthy@nova-eye.com

This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More